NovoCure Limited (NVCR) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

23/25

Growth 5 Margin 5 Expansion 5 Platform 4 Financial 4

latest quarter score

Earnings Reports

23
NovoCure (NVCR) Q2 2026: Optune Pax Scripts Surge 200%, Catalyzing Multi-Indication Growth Trajectory
July 23, 2026
18
NovoCure (NVCR) Q1 2026: Optune Pax Launch Drives 868 Provider Certifications, Accelerating Oncology Pipeline
April 30, 2026
15
NovaCure (NVCR) Q4 2025: Non-GBM Portfolio Targets $25M as Platform Expansion Accelerates
February 26, 2026
11
NovoCure (NVCR) Q3 2025: GBM Patient Base Hits 4,277 as Platform Expansion Prioritizes Four Indications
October 30, 2025
14
Novocure (NVCR) Q2 2025: Optune Lua Drives $2.4M New Revenue as Multi-Indication Pipeline Accelerates
July 24, 2025
16
Novocure (NVCR) Q1 2025: 93 Unique Lung Cancer Prescribers Signal Durable Multi-Indication Pivot
July 07, 2025

Browse all companies